Tests phone-based specialist advice for ambulance crews treating suspected stroke
Tests telestroke advice during ambulance rides for adults with suspected stroke.
Plain-language title generated from the registry record
Registry title: Telestroke Triage in Suspected Stroke Patients
Key facts
- Where
- Leiden, NetherlandsSee the site
Where in Netherlands
- Leiden University Medical CenterLeiden, NetherlandsNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nyika D. Kruyt
- Trial code
- NCT07657117
- Record updated
- 18 September 2026
- Original description
The ASTRAL trial is a randomized study in patients with suspected stroke in the ambulance setting. The study evaluates whether prehospital telestroke consultation, in addition to standard care, can reduce unnecessary stroke code activations and improve patient triage, treatment efficiency, and resource use. Participants are randomized to telestroke triage plus standard care or standard care alone. Outcomes include unnecessary stroke code activation, patient allocation, treatment times, functional outcome, safety, and cost-effectiveness.Read full original descriptionShow less
Ambulance Stroke Triage Assisted by Telemedicine (ASTRAL) Trial.
The ASTRAL trial is a randomized study in patients with suspected stroke in the ambulance setting. The study evaluates whether prehospital telestroke consultation, in addition to standard care, can reduce unnecessary stroke code activations and improve patient triage, treatment efficiency, and resource use. Participants are randomized to telestroke triage plus standard care or standard care alone. Outcomes include unnecessary stroke code activation, patient allocation, treatment times, functional outcome, safety, and cost-effectiveness.
Inclusion: Age 18 years or older; Stroke code activation by ambulance professional during office hours; Symptom onset < 24 hours or uncertain onset; The patient is deemed capable of understanding the study information and making a decision about participation/opt-out.
Exclusion: Age under 18 years.